Chronic myeloid leukaemia caused by the mutant BCR–ABL kinase has been successfully treated with inhibitors of this kinase, such as imatinib, but mutations within the kinase can result in resistance to these drugs. Quintás-Cardama and colleagues discuss novel BCR–ABL inhibitors that have the potential to overcome such resistance.
- Alfonso Quintás-Cardama
- Hagop Kantarjian
- Jorge Cortes